Partial Recovery of Brain Metabolism in Methamphetamine Abusers after Protracted Abstinence

American Journal of Psychiatry

Volumn 161, Issue 2, 2004, Pages 242-248

  Wang, Gene Jack ^a   Volkow, Nora D ^b   Chang, Linda ^b   Miller, Eric ^b   Sedler, Mark ^b   Hitzemann, Robert ^b   Zhu, Wei ^b   Logan, Jean ^b   Ma, Yeming ^b   Fowler, Joanna S ^b  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; FLUORODEOXYGLUCOSE F 18; METHAMPHETAMINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ABSTINENCE; ADULT; ANHEDONIA; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DRUG ABUSE; DRUG DEPENDENCE; DRUG USE; FEMALE; GLUCOSE METABOLISM; HUMAN; MALE; MOTIVATION; MOTOR ACTIVITY; NEUROPHYSIOLOGY; NUCLEUS ACCUMBENS; PERFORMANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THALAMUS; VERBAL MEMORY; ADAPTATION; BRAIN; COGNITIVE DEFECT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONVALESCENCE; METABOLISM; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; SYNAPTOSOME; TIME;

ADAPTATION, PHYSIOLOGICAL; ADULT; AMPHETAMINE-RELATED DISORDERS; BRAIN; COGNITION DISORDERS; CORPUS STRIATUM; DOPAMINE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; METHAMPHETAMINE; NEUROPSYCHOLOGICAL TESTS; PRESYNAPTIC TERMINALS; RADIOPHARMACEUTICALS; RECOVERY OF FUNCTION; THALAMUS; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 12144287701     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.161.2.242     Document Type: Article

References (27)

1. Seiden LS, Sabol KE: Methamphetamine and methylene-dioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction. NIDA Res Monogr 1996; 163:251-276
2. 11C]WIN-35,428. J Neurosci 1998; 18:8417-8422
3. Volkow ND, Chang L, Wang G-J, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, Ding Y-S, Logan J, Wong C, Miller EN: Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001; 158:377-382
4. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ: Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 1996; 2:699-703
5. Ricaurte GA, McCann UD: Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann NY Acad Sci 1992; 648:371-382
6. Friedman SD, Castañeda E, Hodge GK: Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity. Pharmacol Biochem Behav 1998; 61:35-44
7. Cass WA, Manning MW: Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of methamphetamine. J Neurosci 1999; 19:7653-7660
8. Melega WP, Raleigh MJ, Stout DB, Lacan G, Huang SC, Phelps ME: Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey. Brain Res 1997; 766:113-120
9. Harvey DC, Lacan G, Tanious SP, Melega WP: Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss. Brain Res 2000; 871:259-270
10. Volkow ND, Chang L, Wang G-J, Fowler JS, Franceschi D, Sedler M, Gatley SJ, Miller E, Hitzemann R, Ding YS, Logan J: Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 2001; 21:9414-9418
11. Volkow ND, Chang L, Wang G-J, Fowler JS, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, Ding Y-S, Wong C, Logan J: Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers. Am J Psychiatry 2001; 158:383-389
12. Schmidt KC, Lucignani G, Sokoloff L: Fluorine-18-fluorodeoxy-glucose PET to determine regional cerebral glucose utilization: a re-examination. J Nucl Med 1996; 37:394-399
13. Wang G-J, Volkow ND, Roque CT, Cestaro VL, Hitzemann RJ, Cantos EL, Levy AV, Dhawan AP: Functional significance of ventricular enlargement and cortical atrophy in normals and alcoholics as assessed by PET, MRI and neuropsychological testing. Radiology 1992; 186:59-65
14. SPM 99 Software. London, MRC Cyclotron Unit, Hammersmith Hospital, 1999
15. Schwartz WJ, Smith CB, Davidsen L, Savaki H, Sokoloff L, Mata M, Fink DJ, Gainer H: Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat. Science 1979; 205:723-725
16. Burrows KB, Meshul CK: High-dose methamphetamine treatment alters presynaptic GABA and glutamate immunoreactivity. Neuroscience 1999; 90:833-850
17. Larsen KE, Fon EA, Hastings TG, Edwards RH, Sulzer D: Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J Neurosci 2002; 22:8951-8960
18. Deng X, Cai NS, McCoy MT, Chen W, Trush MA, Cadet JL: Methamphetamine induces apoptosis in an immortalized rat striatal cell line by activating the mitochondrial cell death pathway. Neuropharmacology 2002; 42:837-845
19. Pu C, Broening HW, Vorhees CV: Effect of methamphetamine on glutamate-positive neurons in the adult and developing rat somatosensory cortex. Synapse 1996; 23:328-334
20. Hershey T, Black KJ, Stambuk MK, Carl JL, McGee-Minnich LA, Perlmutter JS: Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias. Proc Natl Acad Sci USA 1998; 95:12016-12021
21. Rawson RA, Huber A, Brethen P, Obert J, Gulati V, Shoptaw S, Ling W: Status of methamphetamine users 2-5 years after outpatient treatment. J Addict Dis 2002; 21:107-119
22. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley JS, Pappas N R, Wong CT, Felder C: Increased activity of the temporal insula in subjects with bradycardia. Life Sci 2000; 67:2213-2220
23. Wang G-J, Volkow ND, Fowler JS, Cervany P, Hitzemann RJ, Pappas NR, Wong CT, Felder C: Regional brain metabolic activation during craving elicited by recall of previous drug experiences. Life Sci 1999; 64:775-784
24. Kilts CD, Schweitzer JB, Quinn CK, Gross RE, Faber TL, Muhammad F, Ely TD, Hoffman JM, Drexler KP: Neural activity related to drug craving in cocaine addiction. Arch Gen Psychiatry 2001; 58:334-341
25. Bonson KR, Grant SJ, Contoreggi CS, Links JM, Metcalfe J, Weyl HL, Kurian V, Ernst M, London ED: Neural systems and cue-induced cocaine craving. Neuropsychopharmacology 2002; 26:376-386
26. Franklin TR, Acton PD, Maldjian JA, Gray JD, Croft JR, Dackis CA, O'Brien CP, Childress AR: Decreased gray matter concentration in the insular, orbitofrontal, cingulate, and temporal cortices of cocaine patients. Biol Psychiatry 2002; 51:134-142
27. Bartzokis G, Beckson M, Lu PH, Edwards N, Rapoport R, Wiseman E, Bridge P: Age-related brain volume reductions in amphetamine and cocaine addicts and normal control subjects: implications for addiction research. Psychiatry Res 2000; 98:93-102